Old and new anti-obesity drugs

被引:0
|
作者
Dodangeh, Salimeh [1 ]
Hasani-Ranjbar, Shirin [2 ]
机构
[1] Univ Tehran Med Sci, Endocrinol & Metab Clin Sci Inst, Endocrinol & Metab Res Ctr, Tehran, Iran
[2] Univ Tehran Med Sci, Endocrinol & Metab Clin Sci Inst, Obes & Eating Habits Res Ctr, Tehran, Iran
关键词
Obesity; Overweight; Anti-obesity medication; Weight loss medication; GLUCAGON-LIKE PEPTIDE-1; GLP-1 RECEPTOR AGONIST; WEIGHT-LOSS; CLINICAL ENDOCRINOLOGISTS; APPETITE SUPPRESSION; AMERICAN ASSOCIATION; EXTENDED-RELEASE; GENE-EXPRESSION; OBESE-PATIENTS; DOUBLE-BLIND;
D O I
10.1007/s40200-024-01512-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obesity is a pandemic problem that correlates with a cluster of metabolic factors leading to poor cardiovascular outcomes, morbidity, and an increased risk of overall mortality. It is necessary to approach obesity with a comprehensive treatment plan, which may involve lifestyle modifications (diet, exercise, and behavioral therapy) and pharmacological interventions. This article provides an overview of the mechanisms of action, efficacy, and safety of available long-term anti-obesity drugs and introduces other potential agents under investigation.
引用
收藏
页数:13
相关论文
共 50 条